Fact CheckerSign in

NCT07386613Completed

Feasibility of Home Monitoring of Visual Function in DR

Investigating the Feasibility of Home Monitoring of Visual Function in Populations at High Risk of Developing Diabetic Retinopathy (DR) Using Novel Game-based Technology (OKKO Health)

Source: ClinicalTrials.gov · Last updated 4 Feb 2026

Brief summary (registry, in English)

Diabetes is a serious condition where patients can develop complications in their body including their eyes which can lead to sight loss. Patients with diabetes are encouraged to attend yearly screening appointments at which signs of Diabetic Retinopathy (DR) are assessed. Attendance at these appointments and at any follow-up appointments can be time-consuming and inconvenient for those working. Better ways to monitor changes in vision are needed. Therefore, we are hoping to develop a set of eye tests that a person with diabetes can complete at home on a smartphone in collaboration with researchers at OKKO Health.

Status (registry)
Completed
Study type
Observational
Enrollment
55 (actual)
First submitted
16 Jan 2026
Start date
9 Sept 2023
Primary completion date
20 Jun 2024
Lead sponsor
Queen's University, Belfast
NCT number
NCT07386613

What you commit to

  • Study type: Observational
  • Participants enrolled: 55
  • From 9 Sept 2023 to the primary completion date, 20 Jun 2024
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Serious life-threatening conditions that would preclude attendance in the longitudinal part of the study.
  • Neurological conditions that can impair vision

Age

  • The presence of another ocular disease that impacts vision such as age-related macular degeneration, glaucoma, or active uveitis.

Other

  • Participants who are unable to tap a screen.
  • Any physical limitation that would make the participant unable to attend clinic visits (e.g., patients with arthritis or neck problems who may be unable to sit for a prolonged period of time).

Who the study is looking for

  • Study 1:
  • The 55 participants with Type 1 or Type 2 diabetes must also be a gestational, or dialysis DR patient.
  • Aged 18-70.
  • All participants should have access to one of the following devices on a daily basis: iPhone (X, XS, XR, 11, 11 Pro, 11 Pro Max, SE 2020, 12, 12 Pro, 12 Pro Max, 12 mini); iPad (Pro 11-inch 2nd generation, Pro 12.9-inch 4th generation); Samsung Galaxy S8, S9, S10, A20e or A40; Samsung Galaxy Tab S3; Honor 10 Lite; Motorola G6 or G7 Power or Pixel 3a.
  • All participants should also have the ability to read and understand in English and be able to give informed consent.
  • All participants should also be able to tap the screen of a digital device.
  • All gestational and dialysis participants should be willing to undergo handheld retinal imaging, no pupil dilation is required.
  • Be willing to use the app from home for up to 6 months in between the participant's regular clinic visits.
    • Study 2:
  • The 35 participants with type 1 or type 2 diabetes should have R0 no retinopathy or R1 background changes (this is stated on the letter they receive from the Diabetic Retinal Screening service).
  • Participants must already have a diabetic screening letter dated within 3 months and use a continuous glucose monitor and be willing to share the data from their monitor with the study team. They must also be willing to allow the research team access to their most recent OCT scans which will be accessed by Prof Tunde Peto.
  • All participants should have access to one of the following devices on a daily basis: iPhone (X, XS, XR, 11, 11 Pro, 11 Pro Max, SE 2020, 12, 12 Pro, 12 Pro Max, 12 mini); iPad (Pro 11-inch 2nd generation, Pro 12.9-inch 4th generation); Samsung Galaxy S8, S9, S10, A20e or A40; Samsung Galaxy Tab S3; Honor 10 Lite; Motorola G6 or G7 Power or Pixel 3a.
  • All participants should also have the ability to read and understand in English and be able to give informed consent.
  • All participants should also be able to tap the screen of a digital device

Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Northern Health and Social Care Trust, Antrim Hospital
Coordinator of this site? Confirm its status
AntrimUnited KingdomUnknown status
Belfast Health and Social Care Trust - Belfast City Hospital
Coordinator of this site? Confirm its status
BelfastUnited KingdomUnknown status
Southern Health and Social Care Trust, Craigavon Hospital
Coordinator of this site? Confirm its status
CraigavonUnited KingdomUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.